Authors reported the absence of adverse effects following the treatment of induced skin inflammation using anti-CD1a antibodies, thus supporting the idea that CD1a is a safe and attractive target for cortical T-ALL (coT-ALL) subtypes. Here, CD1A is linked to acute lymphoblastic leukemia.